The Food and Drug Administration has accepted for review Merck & Co. Inc.’s new drug application for an investigational fertility treatment. Merck (NYSE:MRK) is seeking FDA approval of corifollitropin alfa for controlled ovarian stimulation in women participating in assisted reproductive technology.
FDA to Review Experimental Fertility Treatment
